EBAMed SA, an early-stage medical device company pioneering new approaches to proton therapy today announced the enrollment of the first patient in a prospective imaging study using a device that automatically interprets cardiac ultrasound images to uniquely track the motion of the heart. The first patient was enrolled at the Policlinico San Matteo, Pavia (Italy). This important company milestone was reached according to development schedule. The main objectives of the study are to collect cardiac ultrasound data from patients diagnosed with ventricular tachycardia (VT). The investigators will analyze ultrasound image data quality and establish if it is adequate to support the development of an add-on medical device to guide proton-therapy systems…